Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MRUS | US
1.22
2.41%
Healthcare
Biotechnology
30/06/2024
04/10/2024
51.78
50.06
51.86
49.85
Merus N.V. a clinical-stage immuno-oncology company engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128) which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158 which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145 which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129 which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht the Netherlands.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
37.2%1 month
30.4%3 months
29.7%6 months
65.5%-
-
4.36
0.01
0.01
-4.91
70.47
-
-194.57M
3.53B
3.53B
-
-877.99
-
-30.00
-33.39
18.07
10.48
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
5.21
Range1M
5.21
Range3M
12.73
Rel. volume
0.48
Price X volume
13.31M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CRISPR Therapeutics AG | CRSP | Biotechnology | 45.37 | 3.86B | -0.74% | n/a | 11.68% |
MoonLake Immunotherapeutics | MLTX | Biotechnology | 55.28 | 3.48B | 6.68% | n/a | 0.64% |
TG Therapeutics Inc | TGTX | Biotechnology | 22.23 | 3.44B | -0.67% | 35.04 | 63.38% |
Apellis Pharmaceuticals Inc | APLS | Biotechnology | 27.51 | 3.35B | -3.41% | n/a | 179.52% |
Dynegy Inc | DYN | Biotechnology | 32.58 | 3.27B | -8.35% | n/a | 3.32% |
Iovance Biotherapeutics Inc | IOVA | Biotechnology | 10.46 | 3.17B | 7.17% | n/a | 10.63% |
Amicus Therapeutics Inc | FOLD | Biotechnology | 10.6 | 3.14B | 0.09% | n/a | 335.08% |
Xenon Pharmaceuticals Inc | XENE | Biotechnology | 40.73 | 3.09B | -0.27% | n/a | 1.19% |
Rhythm Pharmaceuticals Inc | RYTM | Biotechnology | 49.63 | 3.03B | -2.71% | n/a | 642.15% |
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -4.91 | 0.76 | Cheaper |
Ent. to Revenue | 70.47 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 4.36 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 29.72 | 74.67 | Lower Risk |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 3.53B | 3.73B | Par |